CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026

Key Takeaways

• CC‑18 outperformed semaglutide in mouse weight loss.
• Lean mass increased while fat mass decreased in preclinical models.
• Weight regain reduced by ~58% after CC‑18 discontinuation.
• Non‑human primates showed sustained loss supporting monthly dosing.
• CC‑18 in Lilly’s Catalyze360 program for clinical proof‑of‑concept.

Pulse Analysis

Obesity treatment has been revolutionized by GLP‑1 agonists, yet clinicians increasingly recognize that the quality of weight loss matters as much as the quantity. Loss of lean muscle can undermine metabolic health, physical function, and the durability of weight reduction. CicadaBio’s CC‑18 tackles this challenge by fusing GLP‑1 receptor activation with ActRII pathway blockade, a dual‑mechanism designed to cut fat while sparing or building muscle, positioning it as a next‑generation therapy that prioritizes body‑composition outcomes.

In preclinical studies, CC‑18 demonstrated compelling efficacy. In diet‑induced obesity mice, it delivered superior weight loss compared with semaglutide and uniquely increased lean mass, resulting in a healthier body‑composition profile. Moreover, animals treated with CC‑18 experienced roughly 58% less weight regain after stopping therapy, suggesting more durable results. Non‑human primate trials reinforced these findings, showing sustained weight reduction and pharmacodynamic activity compatible with monthly dosing—a potential advantage for patient adherence and healthcare cost management.

Strategically, the advancement of CC‑18 through Lilly’s Catalyze360 initiative signals strong industry confidence and could accelerate its path to human trials. If clinical data mirror preclinical performance, CC‑18 may capture a sizable share of the $70 billion global obesity market, especially among patients and providers seeking therapies that preserve muscle mass. Its differentiated mechanism and dosing convenience could also influence future regulatory expectations around efficacy endpoints, prompting a shift toward composite measures of weight loss quality rather than weight alone.